Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И.Пирогова» Минздрава России. 117997, Россия, Москва, ул. Островитянова, д. 1; 2ФГБУ «Национальный медицинский исследовательский центр психиатрии и наркологии им. В.П.Сербского» Минздрава России. 119991, Россия, Москва, Кропоткинский пер., д. 23 bobrov2004@yandex.ru
Список исп. литературыСкрыть список 1. Perez DM. Localization of Adrenergic Receptor Subtypes and Transgenic Expression of Fluorescent-Tagged Receptors. In: Perez DM (ed) Brain. Humana Press Inc., 2006; p. 173–204. 2. Berridge CW. Noradrenergic Modulation of Arousal. Brain Res Rev 2008; 58 (1): 1–17. 3. Николлс Д., Мартин Р., Валлас Б., Фукс П. От нейрона к мозгу. Пер. с англ. П.М.Балабана, А.В.Галкина, Р.А. Гиниатуллина и др. М.: Едиториал УРСС, 2003. / Nikolls D., Martin R., Vallas B., Fuks P. Ot neirona k mozgu. Per. s angl. P.M.Balabana, A.V.Galkina, R.A. Giniatullina i dr. M.: Editorial URSS, 2003. [in Russian] 4. Szabadi E. Functional neuroanatomy of the central noradrenergic system. J Psychopharmacol 2013; 27 (8): 659–93. 5. Schlicker E, Feuerstein T. Human presynaptic receptors. Pharmacol Ther 2017; 172: 1–21. 6. Kalk N, Nutt D, Lingford-Hughes A. The role of central noradrenergic dysregulation in anxiety disorders: evidence from clinical studies. J Psychopharmacol 2019; 25 (1): 3–16. 7. Castelino CB, Schmidt MF. What birdsong can teach us about the central noradrenergic system. J Chem Neuroanat 2010; 39 (2): 96–111. 8. Lucki I, O’Leary OF. Distinguishing roles for norepinephrine and serotonin in the behavioral effects of antidepressant drugs. J Clin Psychiatry 2004; 65 (Suppl. 4): 11–24. 9. Ressler KJ, Nemeroff CB. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress Anxiety 2000; 12 (Suppl. 1): 2–19. 10. Stahl SM. Stahl’s essential psychopharmacology: neuroscientific basis and practical application. 4th ed. Cambridge University Press. Cambridge, NY, Melbourne etc.: Cambridge University Press, 2013. 11. Jacobs BL. Norepinephrine-serotonin interactions in brain. Pol J Pharmacol Pharm 1991; 43 (3): 231–923. 12. Blows WT. Neurotransmitters of the brain: serotonin, noradrenaline (norepinephrine), and dopamine. J Neurosci Nurs 2000; 32 (4): 234–823. 13. Guiard BP, El Mansari M, Merali Z, Blier P. Functional interactions between dopamine, serotonin and norepinephrine neurons: an in-vivo electrophysiological study in rats with monoaminergic lesions. Int J Neuropsychopharmacol 2008; 11 (5): 625–39. 14. Melchitzky DS, Austin MC, Lewis DA. Chemical neuroanatomy of the primate brain. In: Schatzberg AF, Nemroff CB (eds). The American Psychiatric Press textbook of psychopharmacology. 3-rd ed. American Psychiatric Publishing, Inc., 2004; p. 69–87. 15. Hensler JG, Artigas F, Bortolozzi A et al. Chapter Nine – Catecholamine/Serotonin Interactions: Systems Thinking for Brain Function and Disease. In: Advances in Pharmacology. A New Era of Catecholamines in the Laboratory and Clinic. L.E.Eiden (ed.). Adv Pharmacol 2013; 68: 167–97. 16. Racagni G, Brunello N. Physiology to functionality: the brain and neurotransmitter activity. Int Clin Psychopharmacol 1999; 14 (Suppl. 1): S3–7. 17. McGrath JC. Localization of a-adrenoceptors: J.R.Vane Medal Lecture. Br J Pharmacol 2015; 172 (5): 1179–94. 18. Mayer P, Imbert T. alpha2-Adrenoreceptor antagonists. IDrugs: Invest Drugs J 2001; 4 (6): 662–76. 19. Alhayek S, Preuss CV. Beta 1 Receptors. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2018. 20. Pazos A, Probst A, Palacios JM. Beta-adrenoceptor subtypes in the human brain: autoradiographic localization. Brain Res 1985; 358 (1–2): 324–8. 21. Lorton D, Davis JN. The distribution of beta-1- and beta-2-adrenergic receptors of normal and reeler mouse brain: an in vitro autoradiographic study. Neurosci 1987; 23 (1): 199–210. 22. Chiti Z, Teschemacher AG. Exocytosis of norepinephrine at axon varicosities and neuronal cell bodies in the rat brain. FASEB J 2007; 21 (10): 2540–50. 23. Bylund DB. Adrenergic Receptors: Historical Perspectives from the 20th Century. In: Perez DM (ed.). The Adrenergic Receptors In the 21st Century, 2006; p. 3–21. 24. Chamberlain SR, Robbins TW. Noradrenergic modulation of cognition: Therapeutic implications. J Psychopharmacol 2013; 27 (8): 694–718. 25. Berridge C. Role of IL-17 and Th17 Cells in HSV Induced Corneal Immunopathology. Brain Res 2008; 58 (1): 1–17. 26. Atzori M, Cuevas-Olguin R, Esquivel-Rendon E et al. Locus coeruleus norepinephrine release: a central regulator of CNS spatio-temporal activation? Front Synaptic Neurosci 2016; 8, art 25. 27. Elenkov IJ, Wilder RL, Chrousos GP, Vizi ES. The sympathetic nerve-an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev 2000; 52 (4): 595–638. 28. Raison CL, Miller AH. Brain-immune system interactions. In: Schatzberg AF, Nemroff CB (eds). The American Psychiatric Press textbook of psychopharmacology. 3-rd ed. American Psychiatric Publishing, Inc., 2004; p. 147–62. 29. Feinstein DL, Kalinin S, Braun D. Causes, consequences, and cures for neuroinflammation mediated via the locus coeruleus: noradrenergic signaling system. J Neurochem 2016; 139: 154–78. 30. Takenaka MC, Guereschi MG, Basso AS. Neuroimmune interactions: dendritic cell modulation by the sympathetic nervous system. Seminars in Immunopathology. Springer Verlag 2017; 39: 165–76. 31. Vitrac C, Benoit-Marand M. Monoaminergic Modulation of Motor Cortex Function. Front Neural Circuits 2017; 11: 72. 32. Samuels E, Szabadi E. Functional Neuroanatomy of the Noradrenergic Locus Coeruleus: Its Roles in the Regulation of Arousal and Autonomic Function Part II: Physiological and Pharmacological Manipulations and Pathological Alterations of Locus Coeruleus Activity in Humans. Curr Neuropharmacol 2008; 6 (3): 254–85. 33. Alpert M, Allan E, Citrome L. A double-blind, placebocontrolled study of adjunctive nadolol in the management of violent psychiatric patients. Psychopharmacol Bull 1990; 26 (3): 367–71. 34. Yamamoto KI, Shinba T, Yoshii M. Psychiatric symptoms of noradrenergic dysfunction: A pathophysiological view. Psychiatry Clin Neurosci 2014; 68 (1): 1–20. 35. Citrome L, Volavka J. The psychopharmacology of violence: making sensible decisions. CNS Spectr 2014; 19 (5): 411–8. 36. Марри Р., Греннер Д., Мейес П., Родуэлл В. Биохимия человека: В 2 т. Т. 2. Пер. с англ. М.: Мир, 1993. / Marri R., Grenner D., Meies P., Roduell V. Biokhimiia cheloveka: V 2 t. T. 2. Per. s angl. M.: Mir, 1993. [in Russian] 37. Zigmond RE, Schwarzschild MA, Rittenhouse AR. Acute Regulation of Tyrosine Hydroxylase by Nerve Activity and by Neurotransmitters Via Phosphorylation. Annu Rev Neurosci 1989; 12 (1): 415–61. 38. Green AR, Costain DW. Pharmacology and biochemistry of psychiatric disorders. Hampshire: John Wiley & Sons Ltd., 1984. 39. Kopin IJ. Monoamine oxidase and catecholamine metabolism. J Neural Transm (Suppl.) 1994; 41: 57–67. 40. Аляутдин Р.Н. Фармакология. 2-е изд. М.: ГЭОТАР-МЕД, 2004. / Aliautdin R.N. Farmakologiia. 2-e izd. M.: GEOTAR-MED, 2004. [in Russian] 41. Харкевич Д.А. Фармакология. Учебник. ГЭОТАР-Медиа, 2017. / Kharkevich D.A. Farmakologiia. Uchebnik. GEOTAR-Media, 2017. [in Russian] 42. Ghaemi SN. A New Nomenclature for Psychotropic Drugs. J Clin Psychopharmacol 2015; 35 (4): 1. 43. Мосолов С.Н. Основы психофармакологии. М.: Восток, 1996. / Mosolov S.N. Osnovy psikhofarmakologii. M.: Vostok, 1996. [in Russian] 44. Caraci F, Enna SJ, Zohar J et al. A new nomenclature for classifying psychotropic drugs. Br J Clin Pharmacol 2017; 83 (8): 1614–6. 45. Svensson TH. Alpha-adrenoceptor modulation hypothesis of antipsychotic atypicality. Prog Neuropsychopharmacol. Biol Psychiatr 2003; 27 (7): 1145–58. 46. Minzenberg MJ, Yoon JH. An Index of Relative Central a-Adrenergic Receptor Antagonism by Antipsychotic Medications. Experiment Clin Psychopharmacol 2011; 19: 31–9. 47. Leung JYT, Barr AM, Procyshyn RM et al. Cardiovascular side-effects of antipsychotic drugs: the role of the autonomic nervous syste. Pharmacol Ther 2012; 135 (2): 113–22. 48. Fitzgerald PJ. Is elevated norepinephrine an etiological factor in some cases of schizophrenia? Psychiat Res 2014; 3 (30): 497–504. 49. Ikegami M, Ikeda H, Ohashi T et al. Olanzapine-induced hyperglycemia: possible involvement of histaminergic, dopaminergic and adrenergic functions in the central nervous system. Neuroendocrinology 2013; 98 (3): 224–32. 50. Cai H-L, Li H-D, Yan X-Z et al. Metabolomic analysis of biochemical changes in the plasma and urine of first-episode neuroleptic-naïve schizophrenia patients after treatment with risperidone. J Proteome Res 2012; 11 (8): 4338–50. 51. Björkholm C, Jardemark K, Marcus MM et al. Role of concomitant inhibition of the norepinephrine transporter for the antipsychotic effect of quetiapine. Eur Neuropsychopharmacol 2013; 23 (7): 709–20. 52. Ehnvall A, Sjögren M, Zachrisson OCG, Agren H. Lifetime burden of mood swings and activation of brain norepinephrine turnover in patients with treatment-refractory depressive illness. J Affect Dis 2003; 74 (2): 185–9. 53. Watanabe I, Li G-Y, Imamura Y et al. Association of saliva 3-methoxy-4-hydroxyphenylglycol levels and a later depressive state in older subjects living in a rural community: 3-year follow-up study. Int J Geriatr Psychiatry 2012; 27 (3): 321–6. 54. Montoya A, Bruins R, Katzman MA, Blier P. The noradrenergic paradox: implications in the management of depression and anxiety. Neuropsychiatr Dis Treat 2016; 12: 541–57. 55. Eyding D, Lelgemann M, Grouven U et al. Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. BMJ 2010; 341: 4737. 56. Maneeton N, Maneeton B, Eurviriyanukul K, Srisurapanont M. Efficacy, tolerability, and acceptability of bupropion for major depressive disorder: a meta-analysis of randomized-controlled trials comparison with venlafaxine. Drug Des Devel Ther 2013; 7: 1053–62. 57. Fawcett J, Barkin RL. Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. J Affect Dis 1998; 51 (3): 267–85. 58. Meeker AS, Herink MC, Haxby DG, Hartung DM. The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: a systematic review and meta-analysis. Syst Rev 2015; 4 (1): 21. 59. Wang S-M, Han C, Lee S-J et al. Vilazodone for the Treatment of Depression: An Upd ate. Chonnam Med J 2016; 52 (2): 91. 60. Blier P, El Mansari M. Serotonin and beyond: therapeutics for major depression. Philos Trans R Soc Lond B Biol Sci 2013; 368 (1615): 20120536. 61. Bymaster FP, Zhang W, Carter PA et al. Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Psychopharmacology (Berl) 2002; 160 (4): 353–61. 62. Buoli M, Serati M, Cahn W. Alternative pharmacological strategies for adult ADHD treatment: a systematic review. Expert Rev Neurother 2016; 16 (2): 131–44. 63. Herr KD, Nemeroff CB. Paroxetine. In: Schatzberg AF, Nemeroff CB (eds). The American Psychiatric Press textbook of psychopharmacology. The American Psychiatric Press, 2004; p. 259–81. 64. Gobert A, Rivet JM, Cistarelli L et al. Alpha2-adrenergic receptor blockade markedly potentiates duloxetine- and fluoxetine-induced increases in noradrenaline, dopamine, and serotonin levels in the frontal cortex of freely moving rats. J Neurochem 1997; 69 (6): 2616–9. 65. Dell’Osso B, Palazzo MC, Oldani L, Altamura AC. The noradrenergic action in antidepressant treatments: Pharmacological and clinical aspects. CNS Neurosci Ther 2011; 17 (6): 723–32. 66. Pinder RM. Enhancing central noradrenergic function in depression: is there still a place for a new antidepressant? Neuropsychiatr Dis Treat 2005; 1 (1): 3–7. 67. Li X, Zhu L, Su Y, Fang S. Short-term efficacy and tolerability of venlafaxine extended release in adults with generalized anxiety disorder without depression: A meta-analysis. PLoS One 2017; 12 (10): e0185865. 68. Clark GT, Padilla M, Dionne R. Medication Treatment Efficacy and Chronic Orofacial Pain. Oral Maxillofac Surg Clin North Am 2016; 28 (3): 409–21. 69. Callaghan BC, Price RS, Feldman EL. Distal Symmetric Polyneuropathy: A Review. JAMA 2015; 314 (20): 2172–81. 70. Derry S, Gill D, Phillips T, Moore RA. Milnacipran for neuropathic pain and fibromyalgia in adults. In: Derry S (ed). Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd., 2012; p. CD008244. 71. Thorlund K, Druyts E, Wu P et al. Comparative Efficacy and Safety of Selective Serotonin Reuptake Inhibitors and Serotonin-Norepinephrine Reuptake Inhibitors in Older Adults: A Network Meta-Analysis. J Am Geriatr Soc 2015; 63 (5): 1002–9. 72. Borodovitsyna O, Flamini M, Chandler D. Noradrenergic Modulation of Cognition in Health and Disease. Neural Plast 2017; 2017: 6031478. 73. Mariappan P, Alhasso A, Ballantyne Z et al. Duloxetine, a Serotonin and Noradrenaline Reuptake Inhibitor (SNRI) for the Treatment of Stress Urinary Incontinence: A Systematic Review. Eur Urol 2007; 51 (1): 67–74. 74. Sakakibara R, Ito T, Uchiyama T et al. Effects of Milnacipran and Paroxetine on Overactive Bladder due to Neurologic Diseases: A Urodynamic Assessment. Urol Int 2008; 81 (3): 335–9. 75. Cipriani A, Koesters M, Furukawa TA et al. Duloxetine versus other anti-depressive agents for depression. Cochrane Database Syst Rev 2012; 10: CD006533. 76. Maund E, Guski LS, Gøtzsche PC. Considering benefits and harms of duloxetine for treatment of stress urinary incontinence: a meta-analysis of clinical study reports. CMAJ 2017; 189 (5): E194–203. 77. Carroll FI, Blough BE, Mascarella SW et al. Bupropion and Bupropion Analogs as Treatments for CNS Disorders. In: Advances in pharmacology (San Diego, Calif), 2014; 177–216. 78. Dhillon S, Yang LPH, Curran MP. Bupropion. Drugs 2008; 68 (5): 653–89. 79. Hudziak JJ, Rettew DC. Bupropion. In: Schatzberg AF, Nemeroff CB (eds). The American Psychiatric Press textbook of psychopharmacology. The American Psychiatric Press, 2004; p. 327–39. 80. Apovian CM. Naltrexone/bupropion for the treatment of obesity and obesity with Type 2 diabetes. Future Cardiol 2016; 12 (2): 129–38. 81. Sepede G, Corbo M, Fiori F, Martinotti G. Reboxetine in clinical practice: a review. Clin Ter 2012; 163 (4): e255–62. 82. Gayleard JL, Mychailyszyn MP. Atomoxetine treatment for children and adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD): a comprehensive meta-analysis of outcomes on parent-rated core symptomatology. ADHD Atten Deficit Hyperact Dis 2017; 9 (3): 149–60. 83. Ghanizadeh A. A systematic review of reboxetine for treating patients with attention deficit hyperactivity disorder. Nord J Psychiatry 2015; 69 (4): 241–8. 84. Anttila SA, Leinonen EV. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev 2001; 7 (3): 249–64. 85. Watanabe N, Omori IM, Nakagawa A et al. Mirtazapine versus other antidepressive agents for depression. Cochrane Database Syst Rev 2011; 12: CD006528. 86. Perry LA, Ramson D, Stricklin S. Mirtazapine adjunct for people with schizophrenia. Cochrane Database Syst Rev 2018; 5: CD011943. 87. Schildkraut JJ. The catecholamine hypothesis of affective disorders. A review of supporting evidence. Int J Psychiatry 1967; 4 (3): 203–17. 88. Hirschfeld RM. History and evolution of the monoamine hypothesis of depression. J Clin Psychiatry 2000; 61 (Suppl. 6): 4–6. 89. Peng G, Tian J, Gao X et al. Research on the Pathological Mechanism and Drug Treatment Mechanism of Depression. Curr Neuropharmacol 2015; 13 (4): 514–23. 90. Björkholm C, Monteggia LM. BDNF – a key transducer of antidepressant effects. Neuropharmacology 2016; 102: 72–9. 91. Nestler EJ, Barrot M, DiLeone RJ et al. Neurobiology of depression. Neuron 2002; 34 (1): 13–25. 92. Caraci F, Leggio GM, Salomone S, Drago F. New drugs in psychiatry: focus on new pharmacological targets. F1000Res 2017; 6: 397. 93. Deacon G, Kettle C, Hayes D et al. Omega 3 polyunsaturated fatty acids and the treatment of depression. Crit Rev Food Sci Nutr 2017; 57 (1): 212–23. 94. Solé B, Jiménez E, Martinez-Aran A, Vieta E. Cognition as a target in major depression: New developments. Eur Neuropsychopharmacol 2015; 25 (2): 231–47. 95. Chung SW, Hoy KE, Fitzgerald PB. Theta-burst stimulation: a new form of TMS treatment for depression? Depress Anxiety 2015; 32 (3): 182–92. 96. Parker GB, Brotchie H, Graham RK. Vitamin D and depression. J Affect Dis 2017; 208: 56–61. 97. Penders TM, Stanciu CN, Schoemann AM. Bright Light Therapy as Augmentation of Pharmacotherapy for Treatment of Depression. Prim Care Companion CNS Dis 2016; 18 (5). 98. Williams NR, Schatzberg AF. NMDA antagonist treatment of depression. Curr Opin Neurobiol 2016; 36: 112–7. 99. Беспалов А.Ю., Звартау Э.Э. Нейропсихофармакология антагонистов NMDA-рецепторов. СПб.: Невский Диалект, 2000. / Bespalov A.Iu., Zvartau E.E. Neiropsikhofarmakologiia antagonistov NMDA-retseptorov. SPb.: Nevskii Dialekt, 2000. [in Russian] 100. Arnsten AF. Stress weakens prefrontal networks: molecular insults to higher cognition. 2015; 18 (10): 1376–85. 101. Sos P, Klirova M, Novak T et al. Relationship of ketamine’s antidepressant and psychotomimetic effects in unipolar depression. Neuro Endocrinol Lett 2013; 34 (4): 287–93. 102. Duncan WC, Sarasso S, Ferrarelli F et al. Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder. Int J Neuropsychopharmacol 2013; 16 (2): 301–11. 103. Salvadore G, Cornwell BR, Colon-Rosario V et al. Increased Anterior Cingulate Cortical Activity in Response to Fearful Faces: A Neurophysiological Biomarker that Predicts Rapid Antidepressant Response to Ketamine. Biol Psychiatry 2009; 65 (4): 289–95. 104. Salvadore G, Cornwell BR, Sambataro F et al. Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine. Neuropsychopharmacology 2010; 35 (7): 1415–22. 105. Chandler DJ. Evidence for a specialized role of the locus coeruleus noradrenergic system in cortical circuitries and behavioral operations. Brain Res 2016; 1641 (Pt B): 197–206. 106. Shin LM, Liberzon I. The Neurocircuitry of Fear, Stress and Anxiety Disorders. Neuropsychopharmacology 2010; 35 (1): 169–91. 107. Fettes P, Schulze L, Downar J. Cortico-Striatal-Thalamic Loop Circuits of the Orbitofrontal Cortex: Promising Therapeutic Targets in Psychiatric Illness. Front Syst Neurosci 2017; 11: 25. 108. Peters SK, Dunlop K, Downar J. Cortico-Striatal-Thalamic Loop Circuits of the Salience Network: A Central Pathway in Psychiatric Disease and Treatment. Front Syst Neurosci 2016; 10: 104. 109. Noyes R. Beta-adrenergic blocking drugs in anxiety and stress. Psychiatr Clin North Am 1985; 8 (1): 119–32. 110. Davidson JRT. Pharmacotherapy of social anxiety disorder: what does the evidence tell us? J Clin Psychiatry 2006; 67 (Suppl. 12): 20–6. 111. Lipinska G, Baldwin DS, Thomas KGF. Pharmacology for sleep disturbance in PTSD. Hum Psychopharmacol 2016; 31 (2): 156–63. 112. Deebiec J, LeDoux JE. Noradrenergic Signaling in the Amygdala Contributes to the Reconsolidation of Fear Memory: Treatment Implications for PTSD. Ann N Y Acad Sci 2006; 1071 (1): 521–4. 113. Raskind MA, Dobie DJ, Kanter ED et al. The alpha1-adrenergic antagonist prazosin ameliorates combat trauma nightmares in veterans with posttraumatic stress disorder: a report of 4 cases. J Clin Psychiatry 2000; 61 (2): 129–33. 114. Simpson TL, Saxon AJ, Meredith CW et al. A pilot trial of the alpha-1 adrenergic antagonist, prazosin, for alcohol dependence. Alcohol Clin Exp Res 2009; 33 (2): 255–63. 115. Taylor FB, Martin P, Thompson C et al. Prazosin effects on objective sleep measures and clinical symptoms in civilian trauma posttraumatic stress disorder: a placebo-controlled study. Biol Psychiatry 2008; 63 (6): 629–32. 116. Berger W, Mendlowicz MV, Marques-Portella C et al. Pharmacologic alternatives to antidepressants in posttraumatic stress disorder: A systematic review. Prog Neuro-Psychopharmacology Biol Psychiatry 2009; 33 (2): 169–80. 117. Kolb LC, Burris B, Griffiths S. Propranolol and clonodine in treatmenmt of chronic posttraumatic stress disorders of war. In: van der Kolk BA (ed). Posttraumatic stress disorder: psychological and biological sequelae. Washington DC: American Psychiatric Press, 1984; p. 98–105. 118. Lindgren ME, Fagundes CP, Alfano CM et al. Beta-blockers may reduce intrusive thoughts in newly diagnosed cancer patients. Psychooncology 2013; 22 (8): 1889–94. 119. Davidson J. Drug therapy of posttraumatic stress disorder. Br J Psychiatry 1992; 160: 309–14. 120. Pertovaara A. The noradrenergic pain regulation system: A potential target for pain therapy. Eur J Pharmacol 2013; 716 (1–3): 2–7. 121. Taylor BK, Westlund KN. The noradrenergic locus coeruleus as a chronic pain generator. J Neurosci Res 2017; 95 (6): 1336–46. 122. Obata H. Molecular Sciences Analgesic Mechanisms of Antidepressants for Neuropathic Pain. Int J Mol Sci 2017; 18: 2483. 123. Ossipov MH, Dussor GO, Porreca F. Central modulation of pain. J Clin Invest 2010; 120 (11): 3779–87. 124. Strobel C, Hunt S, Sullivan R et al. Science China thematic issue: From brain function to therapy Emotional regulation of pain: the role of noradrenaline in the amygdala. Sci China Life Sci 2014; 57: 384–90. 125. Cortese S, Coghill D. Twenty years of research on attention-deficit hyperactivity disorder (ADHD): looking back, looking forward. Evid Based Ment Heal 2018; 1–4. 126. Castellanos FX, Meyer E. Toward systems neuroscience of shared and distinct neural effects of medications used to treat attention-deficit/hyperactivity disorder. Biol Psychiatry 2013; 74 (8): 560–2. 127. Chamberlain SR, Robbins TW. Noradrenergic modulation of cognition: Therapeutic implications. J Psychopharmacol 2013; 27 (8): 694–718. 128. Sonuga-Barke EJS, Castellanos FX. Spontaneous attentional fluctuations in impaired states and pathological conditions: A neurobiological hypothesis. Neurosci Biobehav Rev 2007; 31 (7): 977–86. 129. Buoli M, Serati M, Cahn W. Alternative pharmacological strategies for adult ADHD treatment: a systematic review. Expert Rev Neurother 2016; 16 (2): 131–44. 130. Schmidt FM, Steinberg H, Himmerich H. Differenzialdiagnostik der Bipolaren Störung: historische und klinische Implikationen und Perspektiven. Fortschritte Neurol Psychiat 2015; 83: 74–82. 131. Chan E, Fogler JM, Hammerness PG. Treatment of Attention-Deficit/Hyperactivity Disorder in Adolescents. JAMA 2016; 315 (18): 1997. 132. Dell’Osso B, Palazzo MC, Oldani L, Altamura AC. The Noradrenergic Action in Antidepressant Treatments: Pharmacological and Clinical Aspects. CNS Neurosci Ther 2011; 17 (6): 723–32. 133. Mattes JA. Treating ADHD in Prison: Focus on Alpha-2 Agonists (Clonidine and Guanfacine). J Am Acad Psychiatry Law 2016; 44 (2): 151–7. 134. Naguy A. Clonidine Use in Psychiatry: Panacea or Panache. Pharmacology 2016; 98 (1–2): 87–92. 135. Yamamoto K, Hornykiewicz O. Proposal for anoradrenaline hypothesis of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 913–22. 136. Lechin F, van der Dijs B. Noradrenergic hypothesis of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 777–8. 137. Van Kammen DP, Peters J, Yao J et al. Norepinephrine in acute exacerbations of chronic schizophrenia. Negative symptoms revisited. Arch Gen Psychiatry 1990; 47: 161–8. 138. Kramer MS, Vogel WH, DiJohnson C et al. Antidepressants in ‘depressed’ schizophrenic inpatients. A controlled trial. Arch Gen Psychiatry 1989; 46: 922–8. 139. Friedman JI, Adler DN, Temporini HD et al. Guanfacine treatment of cognitive impairment in schizophrenia. Neuropsychopharmacology 2001; 25: 402–9. 140. Friedman JI, Wallenstein S, Moshier E et al. The effects of hypertension and body mass index on cognition in schizophrenia. Am J Psychiatry 2010; 167: 1232–9. 141. Bakshi VP, Geyer MA. Phencyclidine-induced deficits in prepulse inhibition of startle are blocked by prazosin, analpha-1noradrenergic antagonist. J Pharmacol Exp Ther 1997; 283: 666–74. 142. Wahlbeck K, Cheine MV, Gilbody S, Ahonen J. Efficacy of beta-blocker supplementation for schizophrenia: a systematic review of randomized trials. Schizophr Res 2000; 41: 341–7. 143. Laursen TM, Agerbo E, Pedersen CB. Bipolar Disorder, Schizoaffective Disorder, and Schizophrenia Overlap. J Clin Psychiatry 2009; 70 (10): 1432–8. 144. Pearlson GD. Etiologic, Phenomenologic, and Endophenotypic Overlap of Schizophrenia and Bipolar Disorder. Annu Rev Clin Psychol 2015; 11 (1): 251–81. 145. Cardno AG, Rijsdijk FV, Sham PC et al. A twin study of genetic relationships between psychotic symptoms. Am J Psychiatry 2002; 159: 539–45. 146. Бобров А.Е. Выделение системных механизмов психотропного эффекта. В кн.: Научные исследования и проблемы преподавания психиатрии. М.: Наука, 1987; с. 61–3. / Bobrov A.E. Vydelenie sistemnykh mekhanizmov psikhotropnogo effekta. V kn.: Nauchnye issledovaniia i problemy prepodavaniia psikhiatrii. M.: Nauka, 1987; s. 61–3. [in Russian] 147. Yamamoto K, Shinba T, Yoshii M. Psychiatric symptoms of noradrenergic dysfunction: A pathophysiological view. Psychiatry Clin Neurosci 2014; 68: 1–20. 148. Маджидова Я.Н. Цереброваскулярные расстройства на фоне патологического климакса у женщин (клиника, патогенез, лечение). РАМН, НИИ неврологии, 1992. / Madzhidova Ia.N. Tserebrovaskuliarnye rasstroistva na fone patologicheskogo klimaksa u zhenshchin (klinika, patogenez, lechenie). RAMN, NII nevrologii, 1992. [in Russian] 149. Rajkumar AP, Horsdal HT, Wimberley T et al. Endogenous and Antipsychotic-Related Risks for Diabetes Mellitus in Young People With Schizophrenia: A Danish Population-Based Cohort Study. Am J Psychiatry 2017; 174 (7): 686–94. 150. Andreescu C, Varon D. New Research on Anxiety Disorders in the Elderly and an Update on Evidence-Based Treatments. Curr Psychiatry Rep 2015; 17 (7): 53. 151. Amen DG, Krishnamani P, Meysami S et al. Classification of Depression, Cognitive Disorders, and Co-Morbid Depression and Cognitive Disorders with Perfusion SPECT Neuroimaging. J Alzheimer’s Dis 2017; 57 (1): 253–66. 152. Lapiz MDS, Morilak DA. Noradrenergic modulation of cognitive function in rat medial prefrontal cortex as measured by attentional se t shifting capability. Neurosci 2006; 137 (3): 1039–49. 153. Logue SF, Gould TJ. The Neural and Genetic Basis of Executive Function: Attention, Cognitive Flexibility, and Response Inhibition. Pharmacol Biochem Behav 2014; 123: 45–54. 154. Sharma A, Couture J. A Review of the Pathophysiology, Etiology, and Treatment of Attention-Deficit Hyperactivity Disorder (ADHD). Ann Pharmacother 2014; 48 (2): 209–25. 155. Жиляев А.Г. Подходы к диагностике и лечению соматоформной вегетативной дисфункции. В кн.: Психическое здоровье человека XXI века. Сб. науч. статей по материалам Конгресса. 2016; с. 254–7. / Zhiliaev A.G. Podkhody k diagnostike i lecheniiu somatoformnoi vegetativnoi disfunktsii. V kn.: Psikhicheskoe zdorov'e cheloveka XXI veka. Sb. nauch. statei po materialam Kongressa. 2016; s. 254–7. [in Russian] 156. Geiger MJ, Neufang S, Stein DJ, Domschke K. Arousal and the attentional network in panic disorder. Hum Psychopharmacol Clin Exp 2014; 29 (6): 599–603. 157. Быков Ю.В., Беккер Р.А. Пророксан в наркологии и психиатрии (часть 1). Психиатрия и психофармакотерапия им П.Б. Ганнушкина. 2017; 19 (2): 44–51. / Bykov Yu.V., Bekker R.A. Proroxane: a drug with broad efficacy in drug addiction medicine and psychiatry (part 1). Psychiatry and Psychopharmacotherapy. 2017; 19 (2): 44–51. [in Russian] 159. Bobrov AE, Guseva TP. Psychiatric aspects of idiopathic urticaria: a pilot study. J Psychosom Res 2006; 60 (6): 657. 160. Staubach P, Dechene M, Metz M et al. High Prevalence of Mental Disorders and Emotional Distress in Patients with Chronic Spontaneous Urticaria. Acta Derm Venereol 2011; 91 (5): 557–61. 161. Крылов С.С., Старых Н.Т. Фармакологическая характеристика пирроксана. Фармакология и токсикология. 1974; 36 (4): 396–9. / Krylov S.S., Starykh N.T. Farmakologicheskaia kharakteristika pirroksana. Farmakologiia i toksikologiia. 1974; 36 (4): 396–9. [in Russian] 162. Анохин А.Г., Шабанов П.Д. Сравнительная эффективность противоукачивающих свойств пирроксана и дименгидрината у человека. Психофармакол. и биол. наркол. 2005; 5 (1): 850–7. / Anokhin A.G., Shabanov P.D. Sravnitel'naia effektivnost' protivoukachivaiushchikh svoistv pirroksana i dimengidrinata u cheloveka. Psikhofarmakol. i biol. narkol. 2005; 5 (1): 850–7. [in Russian] 163. Быков Ю.В., Беккер Р.А. Пирроксан в психиатрии, неврологии и общесоматической медицине. Часть II. Психиатрия и психофармакотерапия им П.Б. Ганнушкина. 2017; 19 (6): 55–61. / Bykov Yu.V., Bekker R.A. Pyrroxane: a broad efficacy in psychiatry and neurology. Part II. Psychiatry and Psychopharmacotherapy. 2017; 19 (6): 55–61. [in Russian]